Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Zacks Investment Research on MSN1d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Nektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in June
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Morningstar2d
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
WTOP News2d
Nektar: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...
Nektar up 12% to 91c after Oppenheimer upgrade with $6 target
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
Seeking Alpha2d
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.